CARVYKTI: The Revolutionary Cell Therapy Paving the Way for Longer Survival in Multiple Myeloma Patients as Early as Second Line Treatment

Groundbreaking Results from Legend Biotech Corporation’s Phase 3 CARTITUDE-4 Study Introduction SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN), a leading global player in cell therapy, made a significant announcement today. The three-year follow-up data from the Phase 3 CARTITUDE-4 study has shown remarkable results in patients with relapsed or…

Read More

Say Goodbye to Multiple Myeloma: Carvykti – The Revolutionary Cell Therapy that Prolongs Survival!

Say Goodbye to Multiple Myeloma: Carvykti – The Revolutionary Cell Therapy that Prolongs Survival! Description: 45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ —…

Read More

Unlocking the Magic: A Playful and Relatable Look at the Power of Accessing Your Dreams

Ensysce Biosciences, Inc. Faces Delisting from Nasdaq What Happened? Ensysce Biosciences, Inc. (NASDAQ:ENSC) recently received notice from Nasdaq that the company has not met compliance requirements due to its stock price remaining below $1.00 per share for the initial 180-day period. What Does This Mean for Ensysce Biosciences, Inc.? Unfortunately, Ensysce Biosciences, Inc. is now…

Read More

Attention Investors: Bronstein, Gewirtz & Grossman LLC Launches Investigation into Joint Stock Company Kaspi.kz – Take Action Now!

Welcome to our Blog Post! Investigating Potential Claims Against Kaspi.kz Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC is currently investigating potential claims on behalf of purchasers of Joint Stock Company Kaspi.kz (“Kaspi” or “the Company”) (NASDAQ: KSPI). If you have invested in Kaspi securities, we encourage you to obtain additional information and assist with…

Read More

Breaking News: Atos SE Receives Overwhelming Support from Shareholders and Creditors! Find Out Why This Accelerated Safeguard Plan is a Game-Changer

Exciting News from Atos SE! Strong Support for Draft Accelerated Safeguard Plan Paris, France – September 27, 2024 – Atos SE (“Atos” or the “Company”) is thrilled to announce that its shareholders and financial creditors have shown overwhelming support for the proposed draft accelerated safeguard plan. All three classes of affected parties have voted in…

Read More

Act Fast: Don’t Miss Your Chance to Join the CrowdStrike Class Action Lawsuit – Deadline Approaching!

The Impact of a Securities Class Action Lawsuit on CrowdStrike Holdings, Inc. Background In a recent announcement, the law firm of Kessler Topaz Meltzer & Check, LLP revealed that a securities class action lawsuit has been filed against CrowdStrike Holdings, Inc. This lawsuit, filed in the United States District Court for the Western District of…

Read More